Get the Stockscreener App
8.89
0.11%
-0.010
After Hours:
8.78
-0.11
-1.24%
Cyclacel Pharmaceuticals Inc stock is traded at $8.89, with a volume of 89,575.
It is down -0.11% in the last 24 hours and up +168.58% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
See More
Previous Close:
$8.90
Open:
$8.72
24h Volume:
89,575
Relative Volume:
0.03
Market Cap:
$14.08M
Revenue:
$74,000
Net Income/Loss:
$-13.43M
P/E Ratio:
-0.9457
EPS:
-9.4
Net Cash Flow:
$-10.54M
1W Performance:
-0.89%
1M Performance:
+168.58%
6M Performance:
+49.48%
1Y Performance:
-61.68%
1-Day Range:
$8.13
$8.9249
1-Week Range:
$8.13
$10.08
52-Week Range:
$0.215
$39.84
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Compare CYCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
8.89 | 14.74M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Apr-27-20 | Resumed | ROTH Capital | Buy |
| Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-15 | Initiated | H.C. Wainwright | Buy |
| Feb-04-10 | Initiated | Roth Capital | Buy |
| Oct-28-09 | Initiated | Merriman | Buy |
| Aug-12-08 | Initiated | Piper Jaffray | Buy |
| Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-12-08 | Reiterated | Collins Stewart | Buy |
| Mar-12-08 | Reiterated | Needham & Co | Buy |
| Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-04-07 | Reiterated | Needham & Co | Buy |
| Apr-23-07 | Initiated | Lazard Capital | Buy |
| Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Cyclacel Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Cyclacel Pharmaceuticals Implements Reverse Stock Split in July - MSN
Cyclacel Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Cyclacel reports Q2 financials, declares $0.15/share dividend. - AInvest
Cyclacel Pharmaceuticals, Inc. Reports Second Quarter 2025 Financial Results and Business Developments - Quiver Quantitative
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Pharmaceuticals Slashes Losses to $1.3M, Plans Strategic Malaysian Expansion - Stock Titan
Cyclacel Pharmaceuticals files audited Q1 financials to support S-3 eligibility - Investing.com Canada
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Globe and Mail
What makes Cyclacel Pharmaceuticals Inc. stock price move sharplyFree Momentum Stock List - thegnnews.com
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors - The Globe and Mail
Cyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERS - MSN
Cyclacel (CYCC) Stock Sees Strong Pre-Market Performance After New Study Results - 富途牛牛
Cyclacel Pharmaceuticals Inc. (CYCC) Soars 34.86% on Encouraging Preclinical Results - AInvest
Cyclacel Pharmaceuticals Stock Up 34.6% In Massive After-Hours Rally - Benzinga
Major Shareholder Cashes Out on Cyclacel Pharmaceuticals Stock! - TipRanks
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - The Manila Times
Cyclacel Pharmaceuticals Highlights Promising Preclinical Study on Plogosertib for Treating Biliary Tract Cancer - Quiver Quantitative
Breakthrough: Novel Drug Plogosertib Effectively Targets Aggressive Biliary Cancer, Study Reveals Key Biomarker - Stock Titan
WeightWatchers Reschedules Second Quarter 2025 Earnings Release and Conference Call to Finalize Fresh Start Accounting Adoption in Connection with Emergence - The Globe and Mail
What are the technical indicators suggesting about Cyclacel Pharmaceuticals Inc.Tap into rapid wealth building techniques - Jammu Links News
What are analysts’ price targets for Cyclacel Pharmaceuticals Inc. in the next 12 monthsInvest in stocks with strong fundamentals - Jammu Links News
Is Cyclacel Pharmaceuticals Inc. stock overvalued or undervaluedAchieve breakthrough gains with expert advice - Jammu Links News
What are Cyclacel Pharmaceuticals Inc. company’s key revenue driversDynamic investment opportunities - Jammu Links News
How volatile is Cyclacel Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough gains with smart trades - Jammu Links News
How does Cyclacel Pharmaceuticals Inc. compare to its industry peersUnlock powerful trading tools for investors - Jammu Links News
What is the dividend policy of Cyclacel Pharmaceuticals Inc. stockInvest smarter with actionable stock recommendations - Jammu Links News
What institutional investors are buying Cyclacel Pharmaceuticals Inc. stockHigh-yield investments - Jammu Links News
What drives Cyclacel Pharmaceuticals Inc. stock priceCapitalize on stocks with high profit margins - Jammu Links News
Should I hold or sell Cyclacel Pharmaceuticals Inc. stock in 2025Maximize returns with timely market signals - Jammu Links News
When is Cyclacel Pharmaceuticals Inc. stock expected to show significant growthAchieve breakthrough profits with smart strategies - Jammu Links News
What is the risk reward ratio of investing in Cyclacel Pharmaceuticals Inc. stockGet real-time alerts on top stocks - Jammu Links News
Cyclacel Pharmaceuticals Inc. Stock Analysis and ForecastAchieve consistent profits with smart trading - Jammu Links News
What are the latest earnings results for Cyclacel Pharmaceuticals Inc.Unprecedented growth rates - Jammu Links News
What is Cyclacel Pharmaceuticals Inc. company’s growth strategyGame-changing returns - Jammu Links News
Published on: 2025-08-03 02:26:26 - Jammu Links News
3 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire - The Globe and Mail
MELI Set to Report Q2 earnings: Time to Hold or Fold the Stock? - The Globe and Mail
Is it the right time to buy Cyclacel Pharmaceuticals Inc. stockStock Strategy Recommendation For Every Investor - jammulinksnews.com
IBM Report: Canadians' Data Security Under Increased Threat, While Breach Costs Surge - The Globe and Mail
Using Python tools to backtest Cyclacel Pharmaceuticals Inc. strategiesMomentum Trading Guide with Safety Limits - Newser
What Technical Tools Say About Cyclacel Pharmaceuticals Inc. RecoveryFast Entry High Potential Stock Alerts Triggered - metal.it
Verisign’s Earnings Call: Strong Growth Amid Caution - The Globe and Mail
Celestica Beats Q2 Earnings Estimates on Solid Top-Line Growth - The Globe and Mail
How high can Cyclacel Pharmaceuticals Inc. stock goAI Trade Signal Forecast with Chart Logic - Newser
Custom strategy builders for tracking Cyclacel Pharmaceuticals Inc.Free Daily Momentum Screener With Alerts - Newser
Cyclacel Pharmaceuticals Inc. recovery potential after sell offWeekly Gain Forecast with Momentum Indicators - Newser
Full technical analysis of Cyclacel Pharmaceuticals Inc. stockProven Trading System with Consistent Gains - Newser
What the charts say about Cyclacel Pharmaceuticals Inc. todayConservative Asset Allocation Risk Analysis - Newser
Why Cyclacel Pharmaceuticals Inc. stock attracts strong analyst attentionReal-Time Entry Signals for Top Stocks - Newser
Is Cyclacel Pharmaceuticals Inc. Starting a New UptrendSector Based Breakout Stock Forecast Issued - metal.it
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):